Recursion Pharmaceuticals, Inc. RXRX
3.74
(0.15)
(3.86%)
as of 25 Sep
- Market cap
- $2.1B
- P/E
- 0.0×
Follow RXRX
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
35.62 | 24.47 | 24.51 | 49.93 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(18.44) | (20.04) | (39.72) | (18.59) | |
P/B ratio |
2.14 | 1.59 | 1.62 | 2.08 | |
Price to Tangible BV |
4.14 | 2.85 | 2.78 | 3.88 | |
EV/Sales |
25.66 | 14.64 | 14.62 | 35.03 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.02) | (3.03) | (2.94) | (3.47) | |
EV/FCF |
(3.97) | (2.96) | (2.87) | (3.40) | |
Quick Ratio |
4.72 | 5.19 | 5.23 | 4.42 | |
Current Ratio |
5.03 | 5.47 | 5.50 | 4.60 | |
Net Debt/EBITDA |
4.68 | 6.00 | 8.31 | 4.31 | |
Debt/Assets |
0.39% | 0.54% | 0.65% | 0.85% | |
Debt/Equity |
0.01 | 0.01 | 0.01 | 0.01 | |
Asset Turnover |
0.04 | 0.05 | 0.05 | 0.04 | |
Operating CF/Net income |
0.81 | 0.69 | 0.43 | 0.72 | |
Capex/Depreciation |
(0.11) | (0.02) | (0.06) | (0.01) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,168.37% | 1,358.10% | 269.96% | 2,339.36% | |
Selling, General and Administrative Expense of Revenue |
541.50% | 534.47% | 94.71% | 804.41% | |
Intangible Assets out of Total Assets |
0.37 | 0.34 | 0.32 | 0.35 | |
Share Based Compensation of Revenue |
254.21% | 343.25% | 66.87% | 487.79% | |
Graham Net Nets |
0.16 | 0.24 | 0.26 | 0.17 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(28.34%) | (39.09%) | (36.19%) | (36.89%) | |
Free Cash Flow Yield |
(18.13%) | (20.19%) | (20.79%) | (20.64%) | |
Revenue per Share |
0.01 | 0.01 | 0.08 | 0.01 | |
Operating CF per Share |
(0.20) | (0.15) | (0.10) | (0.26) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.20) | (0.15) | (0.11) | (0.26) | |
Cash per Share |
1.03 | 1.25 | 1.67 | 1.48 | |
Shareholders Equity per Share |
1.72 | 1.94 | 2.53 | 2.34 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.72 | 1.94 | 2.53 | 2.34 | |
Free Cash Flow |
(107.91) | (81.44) | (47.32) | (117.60) | |
Working Capital |
483.58 | 579.86 | 665.14 | 559.00 | |
Capital Expenditures |
(1.96) | (0.34) | (1.24) | (0.24) | |
Net Current Asset Value |
305.80 | 394.80 | 469.58 | 361.53 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.26 | 0.05 | 0.04 | 0.05 | |
Net Profit Margin |
(1,708.02%) | (1,815.57%) | (304.24%) | (3,135.32%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
18.00 | 29.85 | 36.91 | 12.08 | |
Average Payables |
15.99 | 22.72 | 19.87 | 8.10 | |
Average Assets |
1,257.51 | 1,322.38 | 1,461.36 | 1,063.01 | |
Average Common Equity |
917.07 | 979.36 | 1,082.82 | 785.75 |
Columns are period end dates